股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 腦動極光醫療科技有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06681 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000,000 | USD | 0.0000001 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 500,000,000,000 | USD | 0.0000001 | USD | | 50,000 | ...

Group 1: Hong Kong Stocks - China Metallurgical Group (01618) rose nearly 7%, with institutions stating that the value of this resource-rich construction company needs urgent reassessment [1] - Rongchang Bio (09995) increased over 5%, as its innovative ophthalmic drug RC28 has been submitted for listing, following a partnership with Santen China [1] - Laikang Pharmaceutical-B (02105) surged nearly 6%, with a cumulative increase of 36% over the last three trading days, driven by positive preliminary results from the Phase I clinical MAD study of LAE102 [1] - UBTECH Robotics (09880) rose over 5%, with a report from CMB International recommending UBTECH as the top pick in the humanoid robot sector and raising its target price [1] - Innovent Biologics (09969) increased over 6%, as the company announced the first prescriptions for Tanshitumomab in several provinces [1] - BrainCo-B (06681) surged over 16%, benefiting from policy catalysts in the brain-computer interface industry, with its cognitive impairment digital therapy product having a first-mover advantage [1] - Yaoshi Bang (09885) rose over 10%, with high-margin business accelerating growth and POCT devices expected to see increased deployment in the second half of the year [1] - DCH Holdings (00179) fell over 7%, as Citigroup downgraded its investment rating from "Buy" to "Neutral," citing limited upside potential for the stock [1] - Minmetals Resources (01208) rose over 2%, planning to issue $500 million zero-coupon convertible bonds maturing in 2030 for overseas debt refinancing [1][2] Group 2: US Stocks - Alibaba (BABA.US) rose 4.65%, with Morgan Stanley reiterating an "Overweight" rating and raising the ADR target price from $165 to $200 [3] - Li Auto (LI.US) increased 3.57%, as the Li One officially commenced delivery at the Changzhou smart manufacturing base, with a report indicating that the i6 model's sales performance is expected to outperform the i8 [3] - JD.com (JD.US) rose 0.15%, announcing that the 2025 Double 11 shopping festival will start on October 9 at 8 PM, two days earlier than last year [3] - Xpeng Motors (XPEV.US) increased 1.76%, with the company announcing that the Xpeng MONA M03 has delivered a total of 180,000 units [3] - New Oriental (EDU.US) rose 4.38%, with a report indicating that the overall business development of the group is stabilizing [3] - Merus (MRUS.US) surged 35.97%, following an agreement with Danish biotech company Genmab for a cash acquisition at $97 per share [3] - Novo Nordisk (NVO.US) fell 0.20%, as Morgan Stanley downgraded its rating to "Sell" and reduced the target price from $99 to $47 [4] - MoonLake (MLTX.US) plummeted 89.93%, with trial results for its therapeutic drug falling far below expectations, leading to a significant target price cut by RBC [4] - TSMC (TSM.US) fell 0.05%, reaffirming that it has not engaged in discussions regarding potential investments or collaborations with any companies [4] - Micron Technology (MU.US) rose 4.22%, with Morgan Stanley predicting that the storage industry price increase cycle may continue into next year [4]

值得关注的是，国家药监局最新批准发布了《采用脑机接口技术的医疗器械术语》医疗器械行业标准。 这是中国第一项脑机接口医疗器械标准，为脑机接口医疗器械产业高质量发展奠定基础。该标准将于 2026年1月1日正式实施。 脑动极光-B(06681)拉升逾14%，截至发稿，涨14.08%，报8.5港元，成交额3.11亿港元。 消息面上，近日，工业和信息化部部长李乐成在第25届中国国际工业博览会开幕式上致辞时表示，要实 施培育新兴产业打造新动能行动，统筹技术创新、规模化发展和应用场景建设，加快打造一批新兴支柱 产业；建立未来产业投入增长机制，加强前沿技术研发和应用推广，开辟人形机器人、脑机接口、元宇 宙、量子信息等新赛道，创建一批未来产业先导区。 据了解，脑动极光核心产品是脑功能信息管理平台软件系统，为中国首款获得监管批准的认知障碍数字 疗法产品。公司将脑科学与人工智能技术相结合，其核心产品系统具备虚拟人技术和AI技术等独特技 术优势。作为中国首家开发出针对认知障碍的医疗级数字疗法产品的公司，具有先发优势。其核心产品 已纳入中国30个省份的省级医保报销目录，且公司已成功帮助超过120家医院在中国建立认知中心，其 中包括多家 ...

Group 1 - The stock of Brainstorm Cell Therapeutics Inc. (06681.HK) surged over 14% on September 30, reaching a price of 8.5 HKD [2] - The trading volume amounted to 311 million HKD [2]

据了解，脑动极光核心产品是脑功能信息管理平台软件系统，为中国首款获得监管批准的认知障碍数字 疗法产品。公司将脑科学与人工智能技术相结合，其核心产品系统具备虚拟人技术和AI技术等独特技 术优势。作为中国首家开发出针对认知障碍的医疗级数字疗法产品的公司，具有先发优势。其核心产品 已纳入中国30个省份的省级医保报销目录，且公司已成功帮助超过120家医院在中国建立认知中心，其 中包括多家获得 "国家医学中心" 认证的领先医院，有助于提升产品的可及性和市场推广。 消息面上，近日，工业和信息化部部长李乐成在第25届中国国际工业博览会开幕式上致辞时表示，要实 施培育新兴产业打造新动能行动，统筹技术创新、规模化发展和应用场景建设，加快打造一批新兴支柱 产业；建立未来产业投入增长机制，加强前沿技术研发和应用推广，开辟人形机器人、脑机接口、元宇 宙、量子信息等新赛道，创建一批未来产业先导区。 值得关注的是，国家药监局最新批准发布了《采用脑机接口技术的医疗器械 术语》医疗器械行业标 准。这是中国第一项脑机接口医疗器械标准，为脑机接口医疗器械产业高质量发展奠定基础。该标准将 于2026年1月1日正式实施。 智通财经APP获悉，脑动极 ...

BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） 股份代號 : 6681 2025 中期 報告 2025 Interim Report 中期報告 目錄 2 公司資料 4 業務摘要 6 財務摘要 7 管理層討論與分析 23 企業管治及其他資料 38 簡明綜合財務報表審閱報告 39 簡明綜合損益及其他全面收益表 40 簡明綜合財務狀況表 42 簡明綜合權益變動表 44 簡明綜合現金流量表 45 簡明綜合財務報表附註 66 前瞻性陳述 67 釋義 二零二五年中期報告 公司資料 董事會 執行董事 譚錚先生 （董事會主席） 王曉怡博士 （自2025年6月19日起辭任） 非執行董事 李思睿先生 李明秋女士 Deng Feng先生 獨立非執行董事 林曉波先生 段濤博士 李月中先生 公司總部及中國主要營業地點 中國 浙江省 紹興市越城區 平江路2號 紹興水木灣區科學園 3號樓13層1301室 香港主要營業地點 香港 銅鑼灣 希慎道33號 利園一期19樓1910室 註冊辦事處 #4-210, Governors Sq. 23 Lime Tr ...

Group 1 - Recent trading of Hong Kong stocks related to the "Inbound Concept" has seen significant declines, with Baize Medical (02609) down 19.16% to HKD 9.45, Brain Dynamics (06681) down 18.32% to HKD 8.56, and Yaojie Ankang-B (02617) down 12.62% to HKD 182.8 [1] - Yaojie Ankang announced in August that it would be included in several Hang Seng Index series components, effective from September 8, which includes nine indices such as the Hang Seng Composite Index and the Hang Seng Healthcare Index [1] - The inclusion of Yaojie Ankang in multiple indices has led to passive buying by ETFs tracking these indices, resulting in significant trading activity [1] Group 2 - On September 15, the Guozheng Hong Kong Stock Connect Innovative Drug Index underwent a quarterly adjustment, incorporating Yaojie Ankang as a constituent stock [1] - The largest Hong Kong Stock Connect Innovative Drug ETF purchased 3 million shares of Yaojie Ankang on September 15, amounting to approximately HKD 578 million, which represents about 2.62% of the fund's net asset value [1]

Group 1 - The core viewpoint of the article highlights the recent decline in the stock prices of companies related to the "Hong Kong Stock Connect" concept, particularly Baize Medical, Brainstorm Aurora, and PharmaJet, which saw significant drops of 19.16%, 18.32%, and 12.62% respectively [1] - PharmaJet was recently included in multiple Hang Seng Index series components, effective from September 8, which has led to passive buying by ETFs tracking these indices [1] - The stock price volatility of PharmaJet has affected related ETF products, prompting urgent communication between fund companies and index providers [1] Group 2 - On September 15, the Guozhen Hong Kong Stock Connect Innovative Drug Index underwent a quarterly adjustment, with PharmaJet being added as a constituent stock [1] - The largest Hong Kong Stock Connect Innovative Drug ETF purchased 3 million shares of PharmaJet on September 15, amounting to approximately 578 million HKD, which represents about 2.62% of the fund's net asset value [1]

Key Points - The top three stocks with net inflow of southbound funds are Alibaba-W (09988) with 5.278 billion, Yingfu Fund (02800) with 2.782 billion, and Hang Seng China Enterprises (02828) with 1.566 billion [1] - The top three stocks with net outflow of southbound funds are Xiaomi Group-W (01810) with -0.721 billion, Innovent Biologics (01801) with -0.466 billion, and Pop Mart (09992) with -0.458 billion [1] - In terms of net inflow ratio, Yuexiu Transportation Infrastructure (01052) leads with 63.76%, followed by Crystal International (02232) with 56.34%, and China Resources Gas (01193) with 53.63% [1] - The stocks with the highest net outflow ratio include QuanFeng Holdings (02285) at -59.36%, Yadea Group (01585) at -54.53%, and TCL Electronics (01070) at -54.28% [1] Net Inflow Rankings - The top ten stocks by net inflow include Alibaba-W (09988) with 5.278 billion, Yingfu Fund (02800) with 2.782 billion, and Hang Seng China Enterprises (02828) with 1.566 billion [2] - Other notable stocks in the net inflow list are Meituan-W (03690) with 0.670 billion and Southern Hang Seng Technology (03033) with 0.620 billion [2] Net Outflow Rankings - The top ten stocks by net outflow include Xiaomi Group-W (01810) with -0.721 billion, Innovent Biologics (01801) with -0.466 billion, and Pop Mart (09992) with -0.458 billion [2] - Other significant stocks in the net outflow list are Li Auto-W (02015) with -0.298 billion and China Construction Bank (00939) with -0.254 billion [2] Net Inflow Ratio Rankings - The top three stocks by net inflow ratio are Yuexiu Transportation Infrastructure (01052) at 63.76%, Crystal International (02232) at 56.34%, and China Resources Gas (01193) at 53.63% [3] - Additional stocks with high net inflow ratios include China Ship Leasing (03877) at 49.13% and Jiangsu Ninghu Expressway at 45.49% [3] Net Outflow Ratio Rankings - The stocks with the highest net outflow ratios include QuanFeng Holdings (02285) at -59.36%, Yadea Group (01585) at -54.53%, and TCL Electronics (01070) at -54.28% [3] - Other notable stocks with significant net outflow ratios are Kangji Medical (09997) at -53.77% and QiuTai Technology (01478) at -47.17% [3]

Core Viewpoint - The stock of Brainstorm Aurora-B (06681) experienced significant volatility, reaching a new high of 13.8 HKD before dropping over 14% in the afternoon, with a total trading range of 32% throughout the day [1] Group 1: Stock Performance - The stock had previously risen for four consecutive trading days, accumulating a total increase of 125% [1] - As of the latest report, the stock was down 14.84%, trading at 10.04 HKD, with a total transaction volume of 1.724 billion HKD [1] Group 2: Market Activity - Starting from September 8, Brainstorm Aurora was officially included in the Hong Kong Stock Connect list [1] - On September 9, the company attracted southbound capital for stock accumulation, with northbound investors holding 2.1124 million shares, representing 1.66% of total shares [1] Group 3: Company Overview - Brainstorm Aurora is the first domestic company to develop medical-grade digital therapy products targeting cognitive impairment [1] - Its core product is the first cognitive impairment digital therapy product in China to receive regulatory approval, with the first registration certificate obtained in September 2018 [1] Group 4: Financial Performance - In the first half of this year, the company reported revenue of 100 million RMB, reflecting a year-on-year increase of 92.82% [1] - The adjusted net loss for the same period was 88.022 million RMB, which is an increase of 11.64% year-on-year [1]